Podcasts about antiretroviral therapy

In this episode, Chloe Orkin, MBChB, FRCP, MD, and Jean-Michel Molina, MD, PhD, discuss highlights from CCO's independent conference coverage of CROI 2025, including:Advances in HIV treatment based on results from CARESPotential HIV therapies in the pipeline, such as doravirine/islatravirEffects of broadly neutralizing antibodies on HIV treatment and cure Key clinical data on HIV and STI prevention obtained from PILLAR, HPTN 083, PURPOSE 1, and STOMPPresenters:Chloe Orkin, MBChB, FRCP, MDProfessor of Infection and InequitiesDean for Healthcare TransformationHonorary Consultant Physician, Barts Health NHS TrustFaculty of Medicine and DentistryQueen Mary University of LondonLondon, United KingdomJean-Michel Molina, MD, PhDProfessor of MedicineUniversity of Paris CiteDepartment of Infectious DiseasesSaint-Louis and Lariboisiere Hospitals, APHPParis, FranceLink to full program:bit.ly/3E1bAYQTo access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. 

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Rajesh Gandhi of Harvard Medical School and Massachusetts General Hospital about the new IAS-USA recommendations for HIV treatment and prevention. Dr Gandhi is the Chair of the guidelines panel, which published its recommendations in the Journal of the American Medical Association on December 1, 2024. Dr Gandhi and Dr Saag discuss the process by which the updated guidelines were created and provide an update on what's new in the current edition. They address other important topics like how to treat patients with opportunistic infections, guidance on when to change therapy, and strategies for preventing HIV acquisition. Finally, Dr Gandhi makes recommendations for those using the guidelines, especially those using them for the first time.0:00 – Introduction1:19 – Overview of the guidelines' creation process3:52– New recommendations on when to start antiretroviral therapy6:37 – New guidance on what regimens to start9:34 – Discussion of other agents like bictegravir and dolutegravir in pregnancy10:45 – How to treat patients with an opportunistic infection 14:09 – Concern about immune reconstitution inflammatory syndrome (IRIS)16:33 – Guidance on when to change therapy and providing support21:18 – How do the guidelines help people stay healthy – management of cancer, cardiovascular risk, and weight gain24:41 – Discussion on prevention of HIV and sexually transmitted diseases30:19 – What could not be addressed in the guidelines33:17 – Final comments and how to use the guidelinesResources: https://jamanetwork.com/ __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

Avec Dre Fatima Kakkar, pédiatre-infectiologue, et Marie-Élaine Métras, pharmacienne, nous allons:  Rappeler les notions de base sur le VIH et souligner des enjeux sociaux importants Discuter des différents schémas thérapeutiques d'antirétroviraux pour prévenir la transmission mère-enfant du VIH Distinguer les recommandations sur l'allaitement chez les mères vivant avec le VIH et les traitements préventifs recommandés chez le nourrisson Références:Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States: Management of Infants Born to People With HIV Infection. Department of Health and Human Services. Janvier 2023. Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Department of Health and Human Services. Janvier 2024. Khan S, Tsang KK, Brophy J, Kakkar F, Kennedy VL, Boucoiran I, Yudin MH, Money D, Read S, Bitnun A; Canadian Pediatric & Perinatal HIV/AIDS Research Group, the Infectious Disease Committee of the Society of Obstetricians and Gynaecologists of Canada, the Canadian HIV and Viral Hepatitis Pharmacists Network, and the Association of Medical Microbiology and Infectious Disease Canada. Canadian Pediatric & Perinatal HIV/AIDS Research Group consensus recommendations for infant feeding in the HIV context. J Assoc Med Microbiol Infect Dis Can. 2023 Mar 1;8(1):7-17. Gouvernement du Québec. La thérapie antirétrovirale pour les adultes infectés par le VIH. Décembre 2022. Sections 9.4.1, 9.5 et 9.6.Nesheim SR, FitzHarris LF, Mahle Gray K, Lampe MA. Epidemiology of Perinatal HIV Transmission in the United States in the Era of Its Elimination. Pediatr Infect Dis J. 2019 Jun;38(6):611-616. Programme commun des Nations Unies sur le VIH/sida (ONUSIDA). La voie pour mettre fin au sida : Rapport mondial actualisé sur le sida. 2023.Programme de lait. CHU Sainte-Justine. 2022.-------------------------------------------Captation et montage: Philippe Lacroix, spécialiste en audiovisuel Musique: Samuel Ross  Logo: Équipe des communications et du graphisme du CHU Sainte-Justine Montage pour les réseaux sociaux: Pierre-Antoine Bernard Idée originale, réalisation et animation: Émilie Roy-St-Pierre Collègues, ami(e)s et famille, merci pour votre précieux soutien. En collaboration avec le CHU Sainte-Justine, membre du Réseau mère-enfant de la francophonie.  © mgparkilo 2024 Merci pour l'écoute! Allez mettre une réaction sur vos épisodes préférés, partagez la bonne nouvelle sur Facebook/Instagram et abonnez-vous pour ne rien manquer

In this episode, Jennifer Cocohoba, PharmD, AAHIVP, and David Koren, PharmD, MPH, AAHIVP, FIDSA, cover the most impactful LA ART and LA PrEP clinical studies presented at AIDS 2024, including:The PURPOSE 1 study of twice-yearly lenacapavir injections vs daily oral tenofovir as PrEP in cisgender womenAn open-label extension of HPTN 084 evaluating LA CAB safety during pregnancy48-week data from the IMPAACT 2017/MOCHA study of LA CAB + RPV in adolescents with HIVA substudy of FLAIR evaluating the efficacy, safety, and tolerability of SC self-administration of LA CAB + RPV Presenters:Jennifer Cocohoba, PharmD, AAHIVPProfessor of Clinical PharmacyDepartment of Clinical PharmacyUniversity of California San Francisco School of PharmacySan Francisco, CaliforniaDavid Koren, PharmD, MPH, AAHIVP, FIDSAAdjunct Clinical ProfessorTemple University School of PharmacyClinical Pharmacist SpecialistTemple University Health SystemPhiladelphia, PennsylvaniaTo access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.  See the full program here.

In this episode featuring faculty from the United States and Europe, Aadia I. Rana, MD, and Laurence Slama, MD, PhD, discuss the subtleties of deciding among HIV treatment options in people with adherence challenges.Listen as they debate the potential risks and benefits of long-acting ART in this population, considerations for people with viremia or resistance, recommendations concerning proviral DNA genotyping, and how to interpret guidelines and provide truly patient-centered care. PresentersAadia I. Rana, MD​Professor of Medicine​Division of Infectious Diseases​University of Alabama at Birmingham Heersink School of Medicine​Birmingham, AlabamaLaurence Slama, MD, PhD​Doctor​Department of Infectious Diseases​Hôtel Dieu University Hospital​University Paris Cité​Paris, FranceSee the full program here.https://bit.ly/450Ql2xGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast channel on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Yvonne Gilleece, MB BCh, BAO, FRCP, uses a case study to illustrate why giving people space and time to engage in HIV care on their terms is key to overcoming potential shame and stigma.She discusses how people can be very vulnerable when engaging in HIV care, and trauma-informed care can help address these vulnerabilities in a safe, respectful way. Listen as she gives her perspectives on:Trauma-informed careOvercoming stigma and shameStaying in care Presenter:Yvonne Gilleece, MB BCh, BAO, FRCPHonorary Clinical Professor and Consultant in HIV Medicine & Sexual HealthBrighton & Sussex Medical School and University Hospitals Sussex NHS Foundation TrustChair of the British HIV AssociationLead for HIV & WomenLead for HIV & HepatitisBrighton, United KingdomContent based on an online CME program supported by an educational grant from Gilead Sciences, Inc.Link to full program:https://bit.ly/3xicSeFGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

Dr. Jackie Sherbuk, Assistant Professor of Medicine at the Morsani College of Medicine Division of Infectious Diseases, presents this case-based review of the use of antiretroviral therapy in HIV/AIDS patients. Dr. Sherbuk begins by reviewing and available antireturovial options, including those that are considered first line. She also covers the use of antiretrovirals in special groups, including expectant mothers, elite controllers, treatment experienced patients, HBV/HIV connected patients, and patients with chronic renal insufficiency. Lastly, Dr. Sherbuk discusses the nuances of using co-formulated combinations of antiretrovirals and mentions the newer long-acting injectable preparations.

Continuing with the series on Infectious diseases, we bring forth another interesting session of discussion between Brig (Dr) J Muthukrishnan & Wg Cdr (Dr) Rohit Vashsiht. In this episode, an approach to the use of ART drugs will be discussed in detail. Here you will find everything you need to know about ART.

Episode 17 - CROI 2024 Insights: Progress and Challenges in HIV Antiretroviral Therapy with Dr Barbara Taylor Recorded May 2, 2024 This episode of Going anti-Viral with Dr Michael Saag hosts Dr Barbara Taylor. They discussed topics covered at CROI 2024, including the 95-95-95 goal, long-acting antiretroviral therapies, mental health challenges in HIV care, and the potential for long-acting treatments in other viral diseases like hepatitis C.  00:00 Introduction and Remembering Dr Scott M. Hammer 00:27  CROI 2024 Highlights 02:55 Exploring the 95-95-95 Goal and Challenges in HIV Epidemic Control 09:01 Innovations in Long-Acting Antiretroviral Therapies 14:11 Advancements in Hepatitis C and B Therapies 16:51 COVID-19 Treatments and Resistance Concerns 19:26 Addressing Mental Health in HIV Care__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

In this episode, Tristan J. Barber, MA, MD, FRCP, and Roger Bedimo, MD, MS, FACP, help you decide whether and how to modify ART in virologically suppressed individuals by critically appraising whether using newer agents may improve their treatment satisfaction.Listen to their conversation about their own approaches to evaluating whether each person living with HIV is taking the best ART regimen for them, as well as ways to proactively assess challenges people may be facing with their HIV ART. PresentersTristan J. Barber, MA, MD, FRCP​Consultant in HIV Medicine​Royal Free London NHS Foundation Trust​Honorary Associate Professor​Institute for Global Health​University College London​London, United KingdomRoger Bedimo, MD, MS, FACP​Professor of Medicine​Interim Director, Office of Global Health, UT Southwestern Medical Center​Chief, Infectious Diseases Section, ​VA North Texas Health Care System​Dallas, TexasFollow along with the slides here. https://bit.ly/44N2w2QSee the full program here.https://bit.ly/450Ql2xGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Samantha Strong, PharmD, BCACP, AAHIVP, CDCES, and Nimish Patel, PharmD, PhD, AAHIVP, cover the most impactful clinical studies presented at CROI 2024, including:New data on long-acting ART, including:The CARES study of LA CAB + RPV in a sub-Saharan African population using a public health approachThe IMPAACT 2017 MOCHA study evaluating switching to LA CAB + RPV in adolescents living with HIVThe ACTG A5359 LATITUDE study of LA CAB + RPV in people with adherence challenges to oral ARTUpdated data from San Francisco's Ward 86 Clinic using LA CAB + RPV in people without viral suppression at baselineCase series of LA CAB (± RPV) + LEN for select people living with HIV unable to take oral ART and unable to use LA CAB + RPV aloneData on HIV and STI prevention, including:The impact of Doxy-PEP guideline implementation on STIs in men who have sex with men and transgender women in San FranciscoBIC/FTC/TAF for PEPOffering PrEP following PEPPresenters:Samantha Strong, PharmD, BCACP, AAHIVP, CDCESClinical Director of PharmacyNevada Health CentersLas Vegas, NevadaNimish Patel, PharmD, PhD, AAHIVPProfessor of Clinical PharmacySkaggs School of Pharmacy & Pharmaceutical SciencesUniversity of California, San DiegoLa Jolla, CaliforniaTo access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.See the full program here: https://bit.ly/49x0W6D

Dr. Jackie Sherbuk, Assistant Professor of Medicine at the Morsani College of Medicine Division of Infectious Diseases, presents this case-based review of the use of antiretroviral therapy in HIV/AIDS patients. Dr. Sherbuk begins by reviewing and available antireturovial options, including those that are considered first line. She also covers the use of antiretrovirals in special groups, including expectant mothers, elite controllers, treatment experienced patients, HBV/HIV connected patients, and patients with chronic renal insufficiency. Lastly, Dr. Sherbuk discusses the nuances of using co-formulated combinations of antiretrovirals and mentions the newer long-acting injectable preparations.

In this episode, Gregory Huhn, MD, MPHTM, uses a case study to explore the reasons healthcare professionals and people living with HIV may want to further optimize ART in the setting of viral suppression. To determine the best outcome for this case study, Dr Huhn discusses the reasons individuals may not be satisfied with daily oral ART and examines data to suggest that, for some individuals with virologic suppression, switching to long-acting ART may address internalized HIV stigma.Finally, Dr Huhn takes a look at the optimal candidates for switching to a long-acting ART regimen and settings where proviral DNA genotyping may be considered prior to switching.Presenter:Gregory Huhn, MD, MPHTMInterim Chief, Division of Infectious DiseasesSenior Director of HIV ServicesCook County HIV Integrated ProgramsInterim Medical Director, The RMR CORE CenterProfessor, Division of Infectious DiseasesRush University Medical CenterChicago, IllinoisTo access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.See the full program here.

Listen to Roger Bedimo, MD, MS, FACP, discuss considerations for older people living with HIV, including:Polypharmacy and deprescribingThe risk of cardiovascular events with various ART regimensApproaches for managing weight gainPresenter:Roger Bedimo, MD, MS, FACPProfessor of MedicineInterim Director, Office of Global HealthUT Southwestern Medical CenterChief, Infectious Diseases SectionVA North Texas Health Care SystemDallas, TexasGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.To download the slides:  https://bit.ly/49zrnZsTo view the full online program:https://bit.ly/49x0W6D

In this episode, Dr. Bedimo discusses best practices for individualized care in transgender women living with HIV, including:Providing services in a gender-affirmative care modelProactive counseling on drug-drug interactions with gender-affirming hormone therapyStrategies to reduce adverse eventsPresenter:Roger Bedimo, MD, MS, FACPProfessor of MedicineInterim Director, Office of Global HealthUT Southwestern Medical CenterChief, Infectious Diseases SectionVA North Texas Health Care SystemDallas, TexasGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.To download the slides: https://bit.ly/49zrnZsTo view the full online program:https://bit.ly/49x0W6D

In this podcast episode, Isolde Butler, MD, MPH, a healthcare professional caring for people living with HIV, and Marissa Gonzalez, an individual living with HIV, discuss strategies to improve healthcare professionals' competencies in delivering optimal HIV care from the start to better support patients in overcoming barriers to sustained care engagement.The topics they discuss include: An introduction to the guidelines on ART initiation—start quickly and choose the therapy that is effective and tolerableThe patient experience, from initial diagnosis to treatment selection, noting that where people get diagnosed matters in determining the level of support they will receiveThe complete HIV care team: healthcare professionals, navigators, case managers, behavioral health providers, mental health providers, and so on. Smaller clinics may not be able to provide adequate support to meet all patient needsHow to navigate the first visit after an HIV diagnosis, including patient–provider treatment discussions on the available therapies that can help with stigmaHIV stigma education; navigating the miseducation and misinformationPresenters:Isolde F. Butler, MD, MPHChief Medical OfficerCresentcareNew Orleans, LouisianaMarissa GonzalezChairCommunity Advisory BoardThe Well ProjectLink to full program:https://bit.ly/3TqVnl1

Can early treatment induce remission in children born with HIV? Find out about this and more in today's PV Roundup podcast.

In this episode, Renslow Sherer, MD, discusses managing virologic failure in a person living with HIV who is heavily treatment experienced, including:Guideline recommendations for selecting a new ART regimenOptions for patients with multidrug-resistant HIV from existing drug classes and novel mechanisms of action with no cross-resistanceData from TMB-301 and TMB-311 for ibalizumab, BRIGHTE for fostemsavir, and CAPELLA for lenacapavir on the use of these agents for people living with HIV who are heavily treatment experienced with multidrug-resistant HIVPresenter:Renslow Sherer, MDDirectorInternational HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisTo download the slides:https://bit.ly/3OcqxIETo view the full online program:https://bit.ly/3ZjSFhg

Drs Michael S. Saag and Rajesh Gandhi discuss HIV and Antiretroviral Therapy Guidelines. When to begin treatment, which treatment to choose, and how to treat the whole person, not just the HIV. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/986509). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources HIV Infection and AIDS https://emedicine.medscape.com/article/211316-overview Zidovudine (Rx) https://reference.medscape.com/drug/retrovir-zdv-zidovudine-342639 ddI and d4T Plus Protease Inhibitors https://pubmed.ncbi.nlm.nih.gov/11364012/ HIV-Protease Inhibitors https://pubmed.ncbi.nlm.nih.gov/9562584/ Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection https://pubmed.ncbi.nlm.nih.gov/26192873/ Early Symptomatic HIV Infection https://reference.medscape.com/article/211873-overview IAS-USA https://www.iasusa.org/ Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel https://pubmed.ncbi.nlm.nih.gov/36454551/ Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs https://pubmed.ncbi.nlm.nih.gov/33572956/ Dolutegravir (Rx) https://reference.medscape.com/drug/tivicay-tivicay-pd-dolutegravir-999861 Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy) https://www.medscape.com/viewarticle/941921_4 Dolutegravir/Lamivudine as a First-Line Regimen in a Test-and-Treat Setting for Newly Diagnosed People Living With HIV https://pubmed.ncbi.nlm.nih.gov/34115650/ Tenofovir DF (Rx) https://reference.medscape.com/drug/viread-tenofovir-df-342633 Tenofovir AF (Rx) https://reference.medscape.com/drug/vemlidy-tenofovir-af-1000007 Abacavir (Rx) https://reference.medscape.com/drug/ziagen-abacavir-342600 HLA B 5701 Testing https://www.ncbi.nlm.nih.gov/books/NBK560797/ Dolutegravir/Rilpivirine (Rx) https://reference.medscape.com/drug/juluca-dolutegravir-rilpivirine-1000216 Efficacy and Safety of Dolutegravir-Rilpivirine for Maintenance of Virological Suppression in Adults With HIV-1: 100-Week Data From the Randomised, Open-Label, Phase 3 SWORD-1 and SWORD-2 Studies https://pubmed.ncbi.nlm.nih.gov/31307948/ Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) https://clinicalinfo.hiv.gov/en/glossary/non-nucleoside-reverse-transcriptase-inhibitor-nnrti Cabotegravir/Rilpivirine: The Last FDA-Approved Drug to Treat HIV https://pubmed.ncbi.nlm.nih.gov/35596583/ Anticipating and Managing Drug Interactions: Pharmacokinetics of Long-Acting HIV Treatment and Prevention Formulations https://www.medscape.com/viewarticle/986504 Mpox Vaccination Basics https://www.cdc.gov/poxvirus/mpox/vaccines/index.html COVID-19 Treatment Guidelines https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/summary-recommendations/ Mpox in People With Advanced HIV Infection: A Global Case Series https://pubmed.ncbi.nlm.nih.gov/36828001/ Information for Healthcare Providers: Tecovirimat (TPOXX) for Treatment of Mpox https://www.cdc.gov/poxvirus/mpox/clinicians/obtaining-tecovirimat.html HIV and Opioid Use Disorder: Screening Tools, Chronic Pain Management, and Access to Care in the Outpatient Setting https://www.medscape.com/viewarticle/986506

In this episode, Daniel R. Kuritzkes, MD, and Cristina Mussini, MD, discuss managing ART failure, including:The definitions of virologic blips, low-level viremia, and virologic failure on ARTThe infrequency of failure with resistance on first-line INSTI-based ART and the instances where this has occurred with BIC- and DTG-based ART in clinical trials and in the real worldThe potential reasons for ART failure, including patient/adherence-related factors, HIV-related factors, and regimen-related factorsThe impact of adherence on viral suppression with BIC- and DTG-based ARTDrug-drug interactions as a reason for failure of first-line INSTI-based ARTWhat to do if someone is experiencing virologic failure requiring an ART changeThe use of proviral DNA testing in patients with viral suppression or low-level viremia with ART treatment experienceThe impact of high HIV-1 RNA on ART effectivenessThe impact of NRTI resistance, including the M184V and K65R mutations, on the effectiveness of BIC- and DTG-based ARTStrategies to encourage and measure patient adherence to ART PresentersDaniel R. Kuritzkes, MDHarriet Ryan Albee Professor of MedicineHarvard Medical SchoolChief, Division of Infectious DiseasesBrigham and Women's HospitalBoston, MassachusettsCristina Mussini, MDProfessorDepartment of Infectious DiseasesUniversity of Modena and Reggio EmiliaModena, ItalyLink to full program: https://bit.ly/3HPu4Lk

What is the risk of HIV transmission with low viral loads? Find out about this and more in today's PV Roundup podcast.

In this episode, Renslow Sherer, MD, discusses managing a first ART failure in the setting of COVID-19, including:Guideline recommendations for resistance testingGuideline recommendations for selecting a new ART regimenData on retained efficacy of NRTIs in second-line regimens in the EARNEST and NADIA studiesConsideration of drug‒drug interactions between ART and COVID-19 treatmentPresenter: Renslow Sherer, MDDirector International HIV Training Center Professor of Medicine Section of Infectious Diseases and Global Health Department of Medicine University of Chicago Chicago, Illinois To download the slides: https://bit.ly/3OcqxIE To view the full online program: https://bit.ly/3ZjSFhg

On episode #33 of the Infectious Disease Puscast, Daniel reviews the infectious disease literature for the weeks of 7/6 – 7/19/23. Host: Daniel Griffin Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of Puscast! Links for this episode Early antiretroviral therapy not associated with higher cryptococcal Meningitis mortality in people with HIV in high-income countries (CID) Implementing a rapid Antiretroviral therapy program using starter packs for emergency department patients diagnosed with HIV infection (OFID) Efficacy of a clinical decision rule to enable direct oral challenge in patients with low-risk Penicillin allergy (JAMA) Infectious diseases consultation associated with reduced mortality in gram-negative bacteremia (CID) Positive impact of [18F]FDG-PET/CT on mortality in patients with Staphylococcus aureus Bacteremia explained by immortal time bias (CID) Azithromycin for bacterial watery diarrhea (JID)  Periprosthetic joint infection: current clinical challenges (CID) Old World medieval Treponema pallidum complex treponematosis (JID) Clinical Impact of polymerase chain reaction–based Aspergillus and Azole resistance detection in invasive aspergillosis (CID) Superior accuracy of Aspergillus plasma cell-free DNA PCR over serum galactomannan for the diagnosis of invasive aspergillosis (CID) Tafenoquine co-administered with dihydroartemisinin–piperaquine for the radical cure of Plasmodium vivax malaria (The Lancet) Doubling of cyclosporiasis cases partially attributable to a salad kit (CDC) Efficacy and safety of adjunctive corticosteroids in the treatment of severe community-acquired pneumonia (BMC) Music is by Ronald Jenkees

Drs Michael S. Saag and Roger Bedimo discuss weight gain after starting antiretroviral therapy, including risk factors, long-term outcomes, and patients' well-being. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/986507). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Weight Gain on INSTI-Based HIV Antiretrovirals https://www.medscape.com/viewarticle/916095#vp_2 Lipodystrophy in HIV Clinical Presentation https://emedicine.medscape.com/article/1082199-clinical Protease Inhibitors' Metabolic Side Effects: Cholesterol, Triglycerides, Blood Sugar, and 'Crix Belly.' Interview With Lisa Capaldini, MD. Interview by John S. James https://pubmed.ncbi.nlm.nih.gov/11364559/ Reduced Survival After Serious Non-AIDS Complications https://www.medscape.com/viewarticle/721773 HIV Protease Inhibitor-Related Lipodystrophy Syndrome https://pubmed.ncbi.nlm.nih.gov/10860898/ Antiretroviral Therapy for HIV Infection https://emedicine.medscape.com/article/1533218-overview Integrase Strand Transfer Inhibitor (INSTI) https://clinicalinfo.hiv.gov/en/glossary/integrase-strand-transfer-inhibitor-insti Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) https://clinicalinfo.hiv.gov/en/glossary/non-nucleoside-reverse-transcriptase-inhibitor-nnrti Strategies to Prevent Weight Gain Among Adults https://pubmed.ncbi.nlm.nih.gov/23638485/ Tenofovir Alafenamide (TAF) Clinical Pharmacology https://pubmed.ncbi.nlm.nih.gov/35146360/ Associations Between Integrase Strand-Transfer Inhibitors and Cardiovascular Disease in People Living With HIV: A Multicentre Prospective Study From the RESPOND Cohort Consortium https://pubmed.ncbi.nlm.nih.gov/35688166/ Adipokines, Weight Gain and Metabolic and Inflammatory Markers After Antiretroviral Therapy Initiation: AIDS Clinical Trials Group (ACTG) A5260s https://pubmed.ncbi.nlm.nih.gov/34117756/ Is Tenofovir Disoproxil Fumarate Associated With Weight Loss? https://pubmed.ncbi.nlm.nih.gov/34848586/ Switching From Boosted PIs to Dolutegravir Decreases Soluble CD14 and Adiponectin in High Cardiovascular Risk People Living With HIV https://pubmed.ncbi.nlm.nih.gov/34120186/ Adiponectin: A Fat Cell Hormone That Promotes Insulin Sensitivity https://www.medscape.org/viewarticle/438373 Glucagon-like Peptide-1 Analogues: An Overview https://pubmed.ncbi.nlm.nih.gov/23869296/ Dolutegravir Plus Two Different Prodrugs of Tenofovir to Treat HIV https://pubmed.ncbi.nlm.nih.gov/31339677/ Weight and Metabolic Changes After Switching From Tenofovir Alafenamide (TAF)/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC+DTG and TDF/FTC/Efavirenz (EFV) to TDF/Lamivudine (3TC)/DTG https://pubmed.ncbi.nlm.nih.gov/36519389/ The ADVANCE Study: A Groundbreaking Trial to Evaluate a Candidate Universal Antiretroviral Regimen https://pubmed.ncbi.nlm.nih.gov/28538284/

In this episode, Maunank Shah, MD, PhD, discusses using HIV-ASSIST to optimize treatment for both HIV and hyperlipidemia. Listen as he covers:Hyperlipidemia and cardiovascular disease risk among people living with HIVRecommendations for lipid screening for people living with HIVUsing HIV-ASSIST to support ART treatment decisions for people living with HIV with comorbiditiesHow HIV-ASSIST prioritizes certain ART agents in the setting of hyperlipidemia, including:Deciding between bictegravir, doravirine, dolutegravir, raltegravir, and rilpivirine vs boosted protease inhibitors, including darunavirDeciding between tenofovir disoproxil fumarate and tenofovir alafenamide or abacavirHow HIV-ASSIST incorporates drug‒drug interaction data from the University of Liverpool HIV Drug Interactions Checker and the DHHS guidelines when considering the use of statin therapy with ARTHow HIV-ASSIST further incorporates drug resistance data from the Stanford HIV Drug Resistance DatabaseMaunank Shah, MD, PhD Associate Professor Infectious Diseases Johns Hopkins University Baltimore, Maryland Link to full program: bit.ly/3pwaH2Y

In this episode, Marta Boffito, MD, PhD, FRCP, and Michelle Cespedes, MD, MS, discuss initial ART options, including:Recommended first-line ART options for most PWH according to DHHS, IAS-USA, EACS, BHIVA, and WHO guidelines Data for weight gain after ART initiation with different ARV classes and drugsWeight gain disparities by race and gender after ART initiationData from the RESPOND study including risk factors for weight gain and CV event risk with INSTI vs non-INSTI–based ART The impact of INSTIs on CV events in the Swiss HIV Cohort study Recommendations for ART and contraception for PWH of childbearing potential Drug–drug interactions between first-line ART and contraceptive options Guideline-recommended first-line ART options in pregnancy with a discussion of how these regimens differ from those recommended for most PWH Marta Boffito, MD, PhD, FRCP Consultant Physician Clinical Director, HIV, Sexual and Gender Health, Dermatology Chelsea and Westminster Hospital NHS Foundation Trust Imperial College London London, United Kingdom Michelle Cespedes, MD, MS Professor of Medicine Division of Infectious Disease Department of Medicine Icahn School of Medicine at Mount Sinai New York, New York Link to full program: bit.ly/3HPu4Lk

In this episode, Carolyn Chu, MD, MSc, FAAFP, AAHIVS, discusses using HIV-ASSIST to aid in the selection of an ART regimen for PWH coinfected with HBV and HCV. Listen as she covers:How HIV-ASSIST supports ART selection in primary careUpdates to viral hepatitis recommendations including:               CDC HBV screening and testing recommendations             AASLD simplified HCV treatment approach for PWHHIV-ASSIST for managing HIV/HBV coinfections, including ensuring that NRTIs that are effective for both HIV and HBV are included in an ART regimen and alerting the user when an additional HBV treatment is needed HIV-ASSIST for managing HIV/HCV coinfections, including showing how the HIV-ASSIST tool incorporates drug‒drug interaction considerations from the University of Liverpool HIV Drug Interaction CheckerCarolyn Chu, MD, MSc, FAAFP, AAHIVSChief Clinical OfficerNational Clinician Consultation CenterProfessorClinical Family Community MedicineUniversity of California, San FranciscoSan Francisco, CaliforniaLink to full program: bit.ly/3pwaH2Y    

In this episode, Christine Katlama, MD, and Babafemi Taiwo, MBBS, discuss optimizing ART for people with HIV who are treatment experienced or failing a current ART regimen, including:Recycling agents from the NRTI, NNRTI, INSTI, and PI classes in salvage ART regimensMaintaining NRTIs in second-line and salvage ART regimens, including the use of 3TC, TFV, and ABCART regimen simplificationWhen to perform genotypic resistance testing, including for PWH who have been off ARTWhen to perform DNA genotyping for archived resistance testingConsidering LA CAB + RPV with prior NNRTI exposure, ART resistance, or past adherence concerns with oral ARTUsing boosted DRV + DTG in salvage regimensSwitching from boosted PIs to INSTIs in PWH receiving second-line therapySecond-line regimens with LA CAB + RPV failure Christine Katlama, MD Professor Sorbonne University APHP Paris Head, HIV/Hepatitis Clinical and Research Unit Department of Infectious Diseases Paris, France Babafemi Taiwo, MBBS Gene Stollerman Professor of Medicine Chief, Division of Infectious Diseases Northwestern University Feinberg School of Medicine Chicago, Illinois Link to full program: https://bit.ly/3Z44Gq3

In this episode, Sonya Krishnan, MD, MHS, discusses using HIV-ASSIST to aid in the selection of an ART regimen for a virologically suppressed PWH who is planning a pregnancy. Listen as she covers:How to input patient specific factors into the HIV-ASSIST toolDiscussion of available education sheets to review the data and recommendations for her current ART regimen in pregnancyAn explanation of why some regimens are ranked lower because of adherence factors such as increased pill burden or dosing frequencyGuidelines informing the HIV-ASSIST output, including DHHS and IAS-USA, and the frequency with which updates are incorporatedHow to use the HIV-ASSIST output to guide regimen selection in pregnancyUse of the HIV-ASSIST tool in shared decision-making and patient counselingSonya Krishnan, MD, MHSAssistant ProfessorDivision of Infectious DiseasesJohns Hopkins UniversityBaltimore, MarylandLink to full program: bit.ly/3pwaH2Y

Dr. Jacqueline Sherbuk, Assistant Professor of Medicine at the University of South Florida Morsani Division of Infectious Diseases, presents information on considerations for switching antiretroviral therapy in the HIV positive patient. Dr. Sherbuk begins by presenting the indications for switching therapy (pill burden, adverse effects, etc). Next, she explains various factors to consider when switching regimens, including prior ARV (antiretroviral) history, comorbidities, and so on. Next she covers the reasons for virologic failure, and how resistance assays are crucial to determining the best path forward if ARV agents need to be modified. Dr. Sherbuk then relates the basic principles of choosing a new ARV regimen. Lastly, the speaker discusses several case based examples of switching therapy with explanation of the rationale and best practice approaches in doing so.

In this episode, Daniel R. Kuritzkes, MD, discusses considerations for patients experiencing weight gain on antiretroviral therapy, including:• Commonly implicated antiretroviral therapy regimens and patient populations• Guideline recommendations for management of weight gainPresenter:Daniel R. Kuritzkes, MDHarriet Ryan Albee Professor of MedicineHarvard Medical SchoolChief, Division of Infectious DiseasesBrigham and Women's HospitalBoston, MassachusettsTo download the slides: bit.ly/3odUA9CTo view the full online program: bit.ly/3ZjSFhg

In this episode, Isolde Butler, MD, and Brenda E. Crabtree Ramírez, MD, discuss rapid ART initiation for people newly diagnosed with HIV, including:The HIV care continuum in the United States and Latin AmericaBarriers to HIV diagnosis, including stigma, discriminatory laws and policies, social determinants of health, and lack of access to healthcareFactors that predict delayed care linkage and inconsistent HIV care and treatmentImproved clinical outcomes that have been shown with rapid ART initiation, first in low- and middle-income countries and now worldwideRecommendations for rapid ART—and regimen choices—from the DHHS, IAS-USA, CENSIDA, EACS, and WHORecommendations for transitioning from PrEP to ART when someone seroconverts while receiving either oral PrEP or LA CAB for PrEPBarriers to rapid ART initiation in their individual care settingsThe future of LA injectable ART for initial treatment and rapid initiationIsolde Butler, MDChief Medical OfficerCrescentCareNew Orleans, LouisianaBrenda E. Crabtree Ramírez, MDAssistant Professor, HIV ProgramDepartment of Infectious DiseasesInstituto Nacional de Ciencias Médicas y Nutrición, Salvador ZubiránMexico City, MexicoLink to full program: bit.ly/3HPu4Lk

Dr. Shylah Moore-Pardo, infectious diseases clinician at the James A Haley Veterans Hospital, reviews antiretroviral initiation in HIV positive patients. Dr. Pardo begins by discussing the interpretation of HIV test results. Next, she highlights several unique positive test scenarios. Dr. Pardo then reviews the characteristic serological patterns of acute HIV infection. The speaker then goes on to describe essential components of the initial HIV positive patient encounter. She then relates recommended test and treat strategies compatible with current guidelines. Lastly, she covers the next steps in management for future patient visits.

Andrew Ustianowski, MBBS, FRCP, PhD - What's Right for Me: Individualising Antiretroviral Therapy in People Living With HIV

In this episode, José R. Arribas, MD, and Melissa Badowski, PharmD, MPH, FIDSA, FCCP, BCIDP, BCPS, AAHIVP, discuss optimizing antiretroviral therapy (ART) for people with HIV who are treatment experienced or failing a current ART regimen, including:The use of proviral DNA genotyping for switching therapyMaintaining nucleos(t)ide reverse-transcriptase inhibitors after a first failureThe role of zidovudine in salvage regimensThe use of twice-daily darunavir with protease inhibitor resistance and twice-daily dolutegravir with integrase strand transfer inhibitor resistanceSimplification of regimens and long-acting therapies for people with HIV who are highly treatment experiencedDrug‒drug interactions that may warrant dosing changes to avoid resistance developmentWhen to consider antiretrovirals with novel mechanisms of action, such as fostemsavir, ibalizumab, and lenacapavirThe logistics of dosing, administration, and development of a complete ART regimen that includes novel mechanism antiretroviralsAddressing psychosocial factors to increase the chance of success on a new ART regimenDrug‒drug interactions with novel mechanism agentsHow common ART resistance is for people with HIV in their own practicesThe possibility of using long-acting cabotegravir plus rilpivirine in people with viremia in the futureAddressing low-level viremiaJosé R. Arribas, MDProfessor of MedicineDepartment of MedicineAutónoma University School of MedicineHead, Infectious Diseases UnitDepartment of Internal MedicineHospital La PazMadrid, SpainMelissa Badowski, PharmD, MPH, FIDSA, FCCP, BCIDP, BCPS, AAHIVPClinical Associate ProfessorSection of Infectious Diseases Pharmacotherapy Department of Pharmacy PracticeUniversity of Illinois at Chicago, College of PharmacyChicago, IllinoisLink to full program:bit.ly/3Z44Gq3

In this episode, Eric Florence, MD, PhD, discusses how clinics can prepare for the implementation of long-acting injectable antiretroviral therapy, including:Clinical infrastructureEnsuring adequate space and injection equipmentMaintaining drug supply and temperature requirementsStaffingEnsuring there are staff able to focus on the implementation of LA ART, including well-trained nurses to administer the injectionsImplementing a system for scheduling follow-up injections and providing patient remindersHaving knowledgeable staff available to answer patient questions on their LA ARTEric Florence, MD, PhDPhysicianInternal Medicine, Infectious Diseases & Tropical MedicineUniversity Hospital of AntwerpEdegem, Brussels, BelgiumSee the full program at: https://bit.ly/3CsSvdX

In this episode, Laurence Slama, MD, PhD, describes some of the ways that her clinic is attempting to make IM injections of long-acting antiretroviral therapy more sustainable long term. She explains the logistics of how she has allowed for patients to receive their long-acting cabotegravir and rilpivirine doses through community nurses after receiving the first 3 doses in a clinical setting. She also discusses some of the benefits and challenges of this kind of flexible system for patients and healthcare professionals. Laurence SlamaDoctorDepartment of Infectious DiseasesHôtel Dieu, APHPParis, FranceSee the full program at:https://bit.ly/3CsSvdX

In this episode, Stephane De Wit, MD, PhD, discusses the benefits of long-acting antiretroviral therapy (ART) for migrant populations in Europe—and specifically in Belgium. He also addresses some of the challenges of accessing and following up with those populations.Dr De Wit describes some of the ways that the Belgian healthcare system is set up to improve access to ART. He then explains some of the disease parameters for considering expanding the use of long-acting ART to patients who are not virologically suppressed. Finally, Dr De Wit offers some thoughts about the future of long-acting ART to migrant populations in Belgium.Stephane De Wit, MD, PhDFormer HeadInfectious DiseasesSaint Pierre University HospitalBrussels, BelgiumSee the full program at:https://bit.ly/3HIMAoF

In this episode, Annette Haberl, MD, and William R. Short, MD, MPH, AAHIVS, discuss when to consider an ART switch during pregnancy, including:Current DHHS, EACS, WHO, BHIVA, and German/Austrian guidelines for the use of ARVs in pregnancyWhat data and recommendations for the use of ARVs during pregnancy are currently missing from the guidelinesAvailable data on newer ARVs in the ARV pregnancy registryPharmacokinetic data for newer ARVs including BIC/FTC/TAF and LA CAB + RPV in pregnancyRecommendations for 2-drug ART regimens in pregnancyWhat to do when someone becomes pregnant on a newer ART regimen that is not yet recommended by the guidelinesAnnette Haberl, MDPhysicianHead of HIV and WomenHIVCENTER FrankfurtDepartment of Infectious DiseaseHospital of the Johann Wolfgang Goethe UniversityFrankfurt, GermanyWilliam R. Short, MD, MPH, AAHIVSAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicinePerelman School of Medicine at the University of PennsylvaniaPhiladelphia, PennsylvaniaLink to full program:https://bit.ly/3HPu4Lk

In this episode, Monica Gandhi, MD, MPH, and Chloe Orkin, MBChB, FRCP, MD, discuss considerations for monkeypox, now called mpox, in people with HIV, including:The history of monkeypox (mpox)The current monkeypox (mpox) outbreakWhat we knew about monkeypox (mpox) in PWH prior to the current outbreakData in PWH from an international case series of monkeypox (mpox)CDC data regarding monkeypox (mpox) in PWHMonkeypox (mpox) treatment recommendationsDrug–drug interaction considerations between tecovirimat for monkeypox (mpox) and ARTMonkeypox (mpox) vaccination recommendations for PWHGlobal access to monkeypox (mpox) treatments and vaccinesWhether monkeypox (mpox) is a sexually transmitted infection and the implications of thatOngoing research on monkeypox (mpox) in PWHMonica Gandhi, MD, MPHProfessor of MedicineDivision of HIV, Infectious Diseases, and Global MedicineUniversity of California, San FranciscoMedical DirectorWard 86 HIV ClinicSan Francisco General Hospital San Francisco, CaliforniaChloe Orkin, MBChB, FRCP, MDProfessor of HIVQueen Mary, University of LondonConsultant PhysicianLead for HIV ResearchBarts Health NHS TrustThe Royal London HospitalLondon, United KingdomLink to full program:https://bit.ly/3HPu4Lk

In this episode, Winnie Sseruma and Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD, discuss some of the barriers to genuinely patient-centered HIV care in Africa and offer calls to action for healthcare professionals for responding to patient preferences.They discuss the efforts to improve patient-centered HIV care in the foundations and organizations for which they work. They also address issues related to stigma around HIV and complacency and lack of visibility for HIV.You will then hear them talk through differentiated service delivery in South Africa and Mozambique as models for other parts of Africa. They focus on HIV prevention and some of the difficulties of reaching certain populations to better communicate effective prevention practices.They end with a discussion about the importance of documenting the experiences and stories of people living with HIV.Winnie SserumaInternational Development Consultant London, United KingdomLinda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhDDirectorDesmond Tutu HIV CentrePast PresidentInternational AIDS SocietyFaculty of Health SciencesUniversity of Cape TownCape Town, South AfricaLink to full program:https://bit.ly/3Fxsfkz

In this episode, Iskandar Azwa, MBChB, and patient advocate Andrew Tan Tze Tho discuss barriers to genuinely patient-centered HIV care in Malaysia and the surrounding region and offer calls to action for healthcare professionals for responding to patient preferences.They discuss health literacy programs and other forms of effective health communication, especially with respect to disparate communities. They also address the prevalence of late presentation in Malaysia and the importance of getting people tested and into care earlier.They then discuss the urgency of rapid initiation of antiretroviral therapy, discrepancies in access to health services, and stigma and discrimination.Finally, they discuss the issues preventing newer antiretrovirals from being more readily available to people in the region; the importance of maintaining and refining patient-focused, differentiated care in the face of such disparities; and the role of advocates and healthcare professionals in helping to drive those improvements. Iskandar Azwa, MBChBAssociate ProfessorInfectious Diseases, Faculty of MedicineUniversity of MalayaKuala Lumpur, MalaysiaAndrew Tan Tze ThoPresidentKuala Lumpur AIDS Support Services Society (KLASS)Kuala Lumpur, MalaysiaLink to full program:https://bit.ly/3Fxsfkz

This is 1 of 6 short episodes taken from a webinar on barriers and solutions to expanding pre-exposure prophylaxis (PrEP) uptake in the comprehensive program “Contemporary HIV Treatment and Prevention 2022.” In this episode, Timothy J. Wilkin, MD, MPH, discusses solutions to expanding PrEP uptake. His discussion includes: Potential healthcare professional barriers to prescribing PrEPAddressing the gap in PrEP training for healthcare professionalsExpanding PrEP options to facilitate adherence and persistence: today and in the near futureImmediate PrEP initiation at New York City sexual health clinicsProviding PrEP by telehealthTake-home points on expanding PrEP uptakePresenter: Timothy J. Wilkin, MD, MPHProfessor of MedicineDivision of Infectious DiseasesWeill Medical College of Cornell UniversityNew York, New YorkLink to full program:http://bit.ly/3UFUl2bFollow along with the slides at:https://bit.ly/3EcaYg0

In this episode, Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD​, discusses strategies for and importance of HIV care engagement and reengagement for those who have fallen out of care. Her overview includes:WHO Global Health Strategy on HIVLongitudinal HIV care trajectoriesPromotion of successful care and antiretroviral therapy (ART) adherenceDifferentiated service deliveryImproving care and ART adherence in high-risk groupsPatient perspectives on ART persistence Presenter:Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD​Director​Desmond Tutu HIV Centre​Past President​International AIDS Society​Faculty of Health Sciences​University of Cape TownCape Town, South Africa​Panelists:Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD​Chief and DirectorVHS-Infectious Diseases Medical Centre​DirectorChennai Antiviral Research and Treatment (CART) Clinical Research Site​Voluntary Health Services​Chennai, IndiaChloe Orkin, MBChB, FRCP, MD​Professor of HIVQueen Mary, University of London​Consultant Physician​Lead for HIV ResearchBarts Health NHS Trust​The Royal London Hospital​London, United Kingdom​Babafemi Taiwo, MBBS​Gene Stollerman Professor of Medicine​Chief, Division of Infectious Diseases​Northwestern University Feinberg School of Medicine​Chicago, IllinoisContent based on an online CME program supported by an independent educational grant from Gilead Sciences.Follow along with the slides: https://bit.ly/3dSNoumLink to full program:https://bit.ly/3AE2AV1

In this episode, Paul E. Sax, MD, discusses long-acting (LA) injectables for HIV treatment, including: Guidance on the use of LA cabotegravir (CAB) + rilpivirine (RPV)Risk factors for virologic failure of LA CAB + RPVThe ATLAS-2M studyCombined clinical trials of LA CAB + RPVPractical considerations for LA CAB + RPVImplementation of LA CAB + RPV Switching to LA CAB + RPV without an oral lead-in, including a discussion of the FLAIR extension studySupporting candidates for LA antiretroviral therapy (ART)Discussion of an implementation study of LA CAB + RPV in patients with challenges to oral ART adherence in San FranciscoFuture LA ART The investigational LA HIV capsid inhibitor lenacapavir (LEN)LEN resistance from the CAPELLA and CALIBRATE studiesLEN injection-site reactions in the CAPELLA and CALIBRATE studiesPresenter: Paul E. Sax, MDClinical DirectorHIV Program and Division of Infectious DiseasesBrigham and Women's HospitalProfessor of MedicineHarvard Medical SchoolBoston, MassachusettsLink to full program:https://bit.ly/3VIsDTgFollow along with the slides at:http://bit.ly/3Gh9AKG

In this episode, Marc Thompson and Tristan J. Barber, MA, MD, FRCP, discuss some of the barriers to genuinely patient-centered HIV care in the United Kingdom and offer calls to action for healthcare professionals for responding to patient preferences. They discuss barriers to HIV testing and effectively communicating the benefits of testing to disparate communities. They also talk through the difficulties in maintaining patient engagement in HIV care and the value of using peer support workers in HIV clinics. You will then hear Marc and Dr Barber talk through treatment and prevention practices. They focus on the importance of messaging around U=U: that treatment can make a patient's HIV undetectable, and therefore their HIV is untransmissible. They end with a discussion about changing treatment paradigms and how to keep patients informed and empowered—not overwhelmed—by those changes to help ensure lasting health outcomes.Marc ThompsonDirector, The Love TankCo-founder, PrepsterLondon, United KingdomTristan J. Barber, MA, MD, FRCPHonorary Associate ProfessorInstitute for Global HealthUniversity College LondonConsultant in HIV MedicineIan Charleson Day CentreRoyal Free HospitalLondon, United Kingdom Link to full program:https://www.clinicaloptions.com/hiv/programs/2022/what-pts-want-hiv

In this episode, Deondre Moore and Samantha V. Hill, MD, MPH, discuss some of the barriers to genuinely patient-centered HIV care in the United States and offer calls to action for healthcare professionals for responding to patient preferences. They talk through some of the barriers that patients face, from struggling with unfamiliar medical terminology, to healthcare professional biases, to more structural problems like housing and food scarcity. They also discuss strategies that healthcare professionals can incorporate to provide more comprehensive, inclusive, collaborative HIV care. Samantha V. Hill, MD, MPHAssistant ProfessorDivision of Adolescent MedicineDepartment of PediatricsThe University of Alabama at BirminghamBirmingham, AlabamaDeondre MooreU.S. Partnerships and Community Engagement ManagerPrevention Access CampaignHouston, TexasLink to full program:https://bit.ly/3fsWuij

In this episode, Tristan J. Barber, MA, MD, FRCP, and Darcy Wooten, MD, discuss switching ART with virologic suppression, including:Switching with prior or unknown resistanceData on switching to BIC/FTC/TAF with a preexisting M184V/I mutation from a pooled analysis of 6 phase III studiesThe impact of baseline resistance on outcomes following a switch to BIC/FTC/TAF in Black PWH from the BRAAVE 2020 studyA post hoc analysis of the SALSA study of DTG/3TC outcomes at Week 48 by baseline resistanceData from the SOLAR 3D study on switching to DTG/3TC from a 3- or 4-drug ART regimen with a history of M184VA retrospective analysis of switching to DTG/3TC with archived M184V/I from the French Dat'AIDS CohortSwitching to long-acting ARTGuidance on candidates for LA CAB + RPVData on risk factors for virologic failure with LA CAB + RPVConsidering an ART switch after weight gainData on weight gain after ART initiation by ARV class and drugMean change in weight by sex at Week 96 in the ADVANCE studyDHHS guideline recommendations regarding weight gain with ARTTristan J. Barber, MA, MD, FRCPHonorary Associate ProfessorInstitute for Global HealthUniversity College LondonConsultant in HIV MedicineIan Charleson Day CentreRoyal Free HospitalLondon, United Kingdom  Darcy Wooten, MDAssociate Professor of MedicineDivision of Infectious Diseases and Global Public HealthDepartment of MedicineUniversity of California, San DiegoSan Diego, California

In this episode, Chloe Orkin, MBChB, FRCP, MD, discusses new HIV data from AIDS 2022, including:Prevention strategiesOral therapiesLA therapiesCureCOVID-19 in PWHFacultyChloe Orkin, MBChB, FRCP, MDProfessor of HIVQueen Mary, University of LondonConsultant PhysicianLead for HIV ResearchBarts Health NHS TrustThe Royal London HospitalLondon, United KingdomFollow along with the slides atbit.ly/3SLuhBq

legacycares.orgfallingoutlgbtq.cominstagram: @fallingoutlgbtqpodtwitter: @fallinglgbtqMelissa Grove M.S., LPC has served as Executive Director of Legacy Counseling Center, Inc. since 1999, transforming the agency into the largest provider of mental health services for HIV+ people in the South. The Grace Project National Conference for Women Living with HIV she founded hosts 200 HIV+ women annually. Other projects include founding Legacy Founders Cottage, an AIDS care facility, and creating the centralized housing solution, Homebaseforhousing.org website. Her newest program, Legacy Master Leasing, sublets apartments to homeless people living with HIV. Ms. Grove speaks around the nation on issues pertaining to mental health, relationships, muscular dystrophy, HIV and chronic illness She additionally has a private therapy practice in Dallas, TX.She was named the 2014 Public Citizen of the Year through the North Central Texas National Association of Social Workers, and received the 2015 Black Tie Dinner Kuchling Humanitarian Award. Currently Ms. Grove has served on the National Consumer Advisory Committee for the Muscular Dystrophy Association and consults on the STS4HIV Project, a project of the National Institute on Drug Abuse.